We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioLineRx to Present Successful Results of Phase 1/2 Study for BL-7010
News

BioLineRx to Present Successful Results of Phase 1/2 Study for BL-7010

BioLineRx to Present Successful Results of Phase 1/2 Study for BL-7010
News

BioLineRx to Present Successful Results of Phase 1/2 Study for BL-7010

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioLineRx to Present Successful Results of Phase 1/2 Study for BL-7010"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioLineRx Ltd. has announced that it will present positive safety results of its Phase 1/2 study for BL-7010, a novel polymer for the treatment of celiac disease, at the 16th International Celiac Disease Symposium (ICDS 2015), to take place from June 21-24 in Prague, Czech Republic. The Phase 1/2 results were previously announced in November 2014.

Yotam Nisemblat, BioLineRx Drug Development Director, will present the data in a talk titled BL-7010, a Novel Potential Treatment of Celiac Disease - a Phase 1/2 Safety Study in Celiac Patients, on Wednesday, June 24, in the Novel Treatments session.

BL-7010 was found to be safe and well tolerated in the single-dose phase, and the optimal safe dose for future development was determined in the repeated-dose phase.

The Company is in the final stages of additional non-clinical studies and formulation development for BL-7010 in preparation for the upcoming randomized, placebo-controlled efficacy study, which is expected to commence in the fourth quarter of 2015.

Advertisement